These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 8653663)

  • 1. Prevention and reduction of left ventricular hypertrophy in the elderly.
    Lavie CJ; Milani RV; Messerli FH
    Clin Geriatr Med; 1996 Feb; 12(1):57-68. PubMed ID: 8653663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Left ventricular hypertrophy: how to influence an important risk factor in hypertension.
    Agabiti-Rosei E; Muiesan ML
    J Hypertens Suppl; 1998 Jan; 16(1):S53-8. PubMed ID: 9534098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease.
    Gradman AH; Alfayoumi F
    Prog Cardiovasc Dis; 2006; 48(5):326-41. PubMed ID: 16627048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Left ventricular hypertrophy and heart failure in women.
    Agabiti-Rosei E; Muiesan ML
    J Hypertens Suppl; 2002 May; 20(2):S34-8. PubMed ID: 12183849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Left ventricular hypertrophy and clinical outcomes in hypertensive patients.
    Ruilope LM; Schmieder RE
    Am J Hypertens; 2008 May; 21(5):500-8. PubMed ID: 18437140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Left ventricular hypertrophy: a pressure-independent cardiovascular risk factor.
    Messerli FH; Ketelhut R
    J Cardiovasc Pharmacol; 1993; 22 Suppl 1():S7-13. PubMed ID: 7507540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of myocardial diastolic dysfunction on coronary flow reserve in hypertensive patients with left ventricular hypertrophy.
    Galderisi M; Cicala S; De Simone L; Caso P; Petrocelli A; Pietropaolo L; Celentano A; Mininni N; de Divitiis O
    Ital Heart J; 2001 Sep; 2(9):677-84. PubMed ID: 11666096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Considerations in treating hypertension: focus on risk factors.
    Messerli FH
    J Hum Hypertens; 1990 Dec; 4 Suppl 5():3-6. PubMed ID: 2151045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
    Palmieri V; Devereux RB
    Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypertension and left-ventricular hypertrophy.
    Messerli FH; Aepfelbacher FC
    Cardiol Clin; 1995 Nov; 13(4):549-57. PubMed ID: 8565018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence of left ventricular hypertrophy is a stronger indicator of cardiovascular events than baseline left ventricular mass or systolic performance: 10 years of follow-up.
    Muiesan ML; Salvetti M; Rizzoni D; Monteduro C; Castellano M; Agabiti-Rosei E
    J Hypertens Suppl; 1996 Dec; 14(5):S43-9. PubMed ID: 9120684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prognostic implications of left ventricular hypertrophy in arterial hypertension].
    Kannel WB
    Arch Mal Coeur Vaiss; 1990 Dec; 83 Spec No 4():11-21. PubMed ID: 2150470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decrease of left ventricular mass is a clinically valuable intermediate end-point of antihypertensive treatment.
    Agabiti-Rosei E
    Blood Press Suppl; 1997; 2():13-5. PubMed ID: 9495620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypertensive heart disease.
    Diamond JA; Phillips RA
    Hypertens Res; 2005 Mar; 28(3):191-202. PubMed ID: 16097361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
    Dahlöf B; Devereux R; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Julius S; Kjeldsen S; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
    Am J Hypertens; 1997 Jul; 10(7 Pt 1):705-13. PubMed ID: 9234823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hypertensive cardiopathy. From arterial hypertension to congestive heart failure].
    Nogueira JB
    Rev Port Cardiol; 1999 Jun; 18(6):635-46. PubMed ID: 10422461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electrocardiographic left ventricular hypertrophy and arterial stiffness: the Ohasama study.
    Watabe D; Hashimoto J; Hatanaka R; Hanazawa T; Ohba H; Ohkubo T; Kikuya M; Totsune K; Imai Y
    Am J Hypertens; 2006 Dec; 19(12):1199-205. PubMed ID: 17161763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypertension to heart failure: a pathophysiological spectrum relating blood pressure, drug treatments and stroke.
    Subramaniam V; Lip GY
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):703-13. PubMed ID: 19505285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Left ventricular hypertrophy and cardiovascular risk in hypertension].
    Amabile G
    Ann Cardiol Angeiol (Paris); 1998 Feb; 47(2):86-90. PubMed ID: 9772934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A study of the relationships between angiotensin- converting enzyme gene, chymase gene polymorphisms, pharmacological treatment with ACE inhibitor and regression of left ventricular hypertrophy in essential hypertension patients treated with benazepril.
    He H; Li LM; Cao WH; Sun NL; Liu MZ; Hu YH
    Ann Hum Biol; 2005; 32(1):30-43. PubMed ID: 15788353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.